Sorin Fedeles, PhD, MBA

Dr. Sorin Fedeles is Executive Director of the Polycystic Kidney Disease Outcomes Consortium (PKDOC) at the Critical Path Institute. Prior to C-Path, Sorin was a scientist and faculty member at Yale University School of Medicine where he led a program focused on identifying new targets and pharmacological avenues for the treatment of Autosomal Dominant Polycystic Kidney Disease, the most common genetic cause of end-stage renal disease (ESRD). His previous work has led to publications as first/senior author in Nature Genetics, Journal of Clinical Investigation, JASN, etc., multiple grants from DoD, NIH, and the PKD Foundation (~$7.2+ million out of which ~$5 million as Principal Investigator), and two method-of-use patents. His academic responsibilities included leading research staff, writing grants/manuscripts, budget oversight, teaching, serving as a peer-reviewer on grants and journal submissions, and disseminating research via national/international conferences.

Sorin brings with him understanding of the drug development process, including preclinical research and clinical trials, cross-functional leadership, and expert knowledge of genetic kidney disorders, as well as a passion for identifying new drug development tools that can improve medical care for those living with PKD. Finally, as part of his business training,  Sorin worked in academic technology transfer (as an Entrepreneur-in-Residence/Blavatnik Fellow; co-founded an academic start-up, TargetSite Therapeutics), pharma business development (Boehringer-Ingelheim), and venture capital (Vida Ventures Fellow).

Sorin obtained his undergraduate degree at Hampshire College, followed by a Masters, PhD, and MBA from Yale University. He remains affiliated with Yale University as an Assistant Professor (Adjunct).